Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells.
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
Sustained cortical and subcortical neuromodulation induced by electrical tongue stimulation.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Primary progressive multiple sclerosis-why we are failing.
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Risk alleles for multiple sclerosis identified by a genomewide study.
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
The Oxford English Corpus: Facts about the language, The Story of Dictionaries
The complex role of estrogens in inflammation.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
Safety Study of Combination Therapy with Intramuscular Avonex and Oral CellCept in Patients with Multiple Sclerosis
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.

Pages